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Abstract 
Because of disease progression and the increasing number of treatment options, patients with metastatic breast cancer 
face multiple decisions over time. Our aim was to identify the multiple decisions patients with metastatic breast cancer 
face in order to decide which decision aids will be developed. First, we analyzed the clinical practice guidelines to identify 
decisions encountered by patients with metastatic breast cancer and healthcare professionals. Furthermore, an online 
questionnaire for patients, a focus group interview with patients and interviews with healthcare professionals were 
performed. In addition, we performed a systematic literature research and internet search to identify relevant decision 
support tools and we assessed their quality. Finally, all results were discussed with a mixed group of eight experts, 
consisting of researchers, patients and healthcare professionals and a comprehensive advice was given which decision aid 
to develop. It turned out that patients with metastatic breast cancer and healthcare professionals are confronted with 
eight major decision points regarding treatment and examinations during the care process. We identified four decision 
aids. These tools partially overlap with some of the identified decision points. Experts advised to develop a decision aid 
for patients with metastatic breast cancer that would address all mentioned decision points. We concluded patients with 
metastatic breast cancer and healthcare professionals will benefit from a personalized decision aid in which all eight 
major decision points are addressed. This decision aid would help patients and healthcare professionals to explore 
patients’ personal values and preferences in order to make a well-informed decision. 
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Introduction 
 
The World Health Organisation reports breast cancer as 
the most common cancer in women worldwide. Breast 
cancer is also the principle cause of death from cancer 
among women1. Metastatic breast cancer means that the 
cancer has spread from the breast to a location outside the 
breast and surrounding lymph nodes. Metastases occur in 
bones (85%), liver (40-50%), lungs (15-25%) and brain (6-
16%).2,3 The median survival of patients with metastatic 
breast cancer is approximately two years. However, 
survival can vary from several months to multiple 
years.4Metastatic breast cancer is considered as a non-
curable disease, but the growth of the metastases can be 
controlled for months to years. Treatment is focused on 
slowing disease progression, maintaining well-being and 
preventing and relieving symptoms and complaints.4 
Medical treatment options have increased over the last 
years; different types of chemotherapy, hormone therapy, 
targeted therapy and palliative procedures such as surgery 
and radiotherapy are available.5,6 The treatment plan for an 
individual patient will depend on tumour type, location 
and size of the metastasis and/or tumour, treatment 
history, co-morbidity, age and health of the patient and on 
the patient’s personal preferences and values.4  
 
Because of disease progression and the increasing number 
of treatment options, patients with metastatic breast 
cancer face multiple decisions over time. For example, 
decisions about treatments with similar or unclear 
outcomes, treatments with different procedures and 
potential complications. Furthermore, they also have to 
decide whether or not to undergo examinations that offer 
little or no new insights in disease progression. Ideally, 
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these decisions should be made after patients have 
received enough information to make an informed choice 
and after patients’ personal values and preferences have 
been shared in partnership with the caregiver(s).7 In this 
process of shared decision making, healthcare 
professionals and patients share the best available evidence 
and healthcare professionals support patients to consider 
options, to deliberate and express their preferences in 
order to achieve an informed decision.8,9 
 
Decision support tools - such as decision aids and option 
grids - facilitate the process of shared decision making. 
These tools can take many different forms and vary in 
content and level of complexity.10 The effect of decision 
aids is shown by a systematic review of 86 randomized 
trials. When patients use decision aids, they improve their 
knowledge of the options, feel more informed and more 
clear about what matters most to them, have more realistic 
expectations of benefits and harms of the options and 
participate more actively in decision making. Moreover, 
decision aids help patients to feel more satisfied with their 
decisions and, in many situations, informed patients elect 
for more conservative treatment options.10 Despite the 
obvious beneficial effects of decision aids for patients, 
there is limited decision support available for patients with 
metastatic breast cancer. There has been a plea for 
decision aids that have been developed by means of a well-
documented and systematically applied development 
process, have been user-tested and are open to scrutiny.11 
Our aim was to identify the multiple decisions patients 
with metastatic breast cancer face in order to decide which 
decision aids to develop. To achieve this, our study 
focused on the following three questions: 
1. Which preference-sensitive decisions do patients with 
metastatic breast cancer and healthcare professionals 
encounter during the care process? 
2. Which decision support tools are available for patients 
with metastatic breast cancer and what is their quality? 
3. Which decision aid(s) should be developed? 
 
Methods 
 
1. Which preference-sensitive decisions do patients 
with metastatic breast cancer and healthcare 
professionals encounter during the care process? 
 
To identify preference-sensitive decisions encountered by 
patients with metastatic breast cancer and healthcare 
professionals, we studied the care process and analysed the 
clinical practice guidelines on breast cancer and metastatic 
breast cancer12-15 by using the ‘HARING tool-8’ 
(http://www.ha-ring.nl/en/tool-8).16 This is a tool which 
aims to support the integration of shared decision making 
into the development to clinical practice guidelines. 
Furthermore, we performed an online questionnaire for 
patients, a focus group interview with patients and 
individual interviews with healthcare professionals. 
Online questionnaire 
Patients were approached via the online forum of the 
Dutch Breast Cancer Association (B-force) to gather 
information on their experiences with preference-sensitive 
decision points in the care process. Patients were asked to 
describe which important decision points they had faced, 
their experiences with these decision points, whether and 
what treatment options they were given and how the 
consequences of these options were discussed with them. 
The questionnaire was online for four weeks and a 
qualitative thematic analysis17 by three team members was 
performed to categorize important decision points.  
 
Focus group interview 
A focus group interview with patients was organized: 
patients were selected from the sixty-nine patients that 
responded to the online questionnaire. Selection criteria of 
patients for the interview were ‘willingness to participate’ 
and ‘diversity in decision points’. Fifteen patients were 
invited, nine participated. The focus group interview lasted 
90 minutes and was moderated by two team members. 
Patients were asked to elaborate on their experiences with 
the important decision points identified from the online 
questionnaire and with additional decision points that were 
raised during the focus group. Furthermore, they were 
asked which values were important for their decision 
making process. The focus group was audio recorded. 
Again a qualitative thematic analysis of the results was 
performed by the project team. The summary of the focus 
group meeting was crosschecked with all participating 
patients.  
 
Interviews with healthcare professionals 
Two medical oncologists were interviewed by two 
members of the project team in order to assess what 
preference sensitive decision points they experience in the 
treatment of patients with metastatic breast cancer. The 
topic list for the interview was based on collected 
information on the care process and treatment options 
from guidelines, literature and the patient association. The 
medical oncologists were asked questions about their 
experiences with shared decision making, decision points, 
use of decision aids, patient values, the healthcare process 
and treatment guidelines. Both interviews were audio 
recorded and transcribed verbatim. Two researchers 
independently performed a qualitative thematic analysis. 
Themes were allocated to all important fragments of the 
transcript. Results were cross-checked with the oncologists 
and frequently occurring themes were selected. 
 
2. Which decision support tools are available for 
patients with metastatic breast cancer and what is 
their quality? 
 
We performed a systematic literature and internet search 
to identify decision support tools for patients with 
Decision aid for patients with metastatic breast cancer, van de Haterd, et al. 
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metastatic breast cancer and we assessed their quality and 
usefulness. 
Systematic literature and internet search  
In order to identify existing decision support tools for 
patients with metastatic breast cancer, the databases 
Medline, Embase and the internet were searched. The 
PICO method - a common technique used in evidence-
based medicine to frame and answer a clinical question - 
was used as search strategy (Figure 1). Abstracts of 
selected articles were screened for eligibility by two 
researchers. Inclusion criteria were: metastatic or advanced 
breast cancer, decision support tool, information on the 
development, evaluation or use of the decision aid. In 
addition, an internet search was performed with the same 
search terms, using the snowballing method and reference 
tracking: scanning the reference list of full text papers and 
links to other resources and using judgment to decide 
whether to pursue this further. Specific websites with an 
inventory of decision aids, such as the website of the 
Ottawa Hospital Research Institute (OHRI) and Med-
Decs were consulted.18,19 Furthermore, an international 
network of experts and organisations on shared decision 
making and experts on breast cancer care were contacted 
to receive more specific information on articles or decision 
aids.  
 
Assessment of quality of available decision aids on 
metastatic breast cancer 
The quality of the decision aids was assessed by two 
researchers using the International Patient Decision Aid 
Standards (IPDAS) criteria.19 The IPDAS criteria are 
divided into three categories: content (28 criteria), 
development process (29 criteria), effectiveness (7 criteria). 
If a decision aid complies with all criteria, it receives the 
maximum quality score of 100%. 
 
3. Which decision aid(s) should be developed? 
 
All results were summarized and discussed with a mixed 
team of experts: one caregiver, two patient representatives, 
two experts on decision aids and shared decision making 
and four researchers. Every member was asked to express 
their opinion and advice on which decision aid should be 
developed. Criteria for selection were ‘relevant for the 
majority of patients’, ‘meeting information needs’ and 
‘available information on benefits and risks of options’. 
Consensus was searched for and unanimously one advice 
on what decision aid should be developed was formulated. 
Results 
 
1. Which preference-sensitive decisions do patients 
with metastatic breast cancer and healthcare 
professionals encounter during the care process? 
 
Clinical practice guidelines 
None of the relevant clinical practice guidelines contained 
explicit information on preference-sensitive decisions 
during the care process.  
 
Online questionnaire 
In total, 69 patients with metastatic breast cancer 
completed the online questionnaire on their experiences 
with preference-sensitive decision points in the care 
process. Fourteen respondents stated they did not receive 
enough information from their healthcare professionals. 
They missed information on the various treatment 
options, medical information on the disease and the 
medication (side-effects, prognosis) and options for end of 
life care. Seven respondents stated they did not mind not 
being able to choose; they trusted their caregiver to make 
the best choice for them. Patients named seven general 
categories of decision points: ‘participating in a scientific 
trial’, ‘dosing schedule’ and ‘method of administration’, 
‘starting a treatment’, ‘stopping a treatment’, ‘proceeding 
treatment’, ‘transferring to another treatment, caregiver or 
hospital’ (Figure 2). Five patients also mentioned that they 
faced non-medical decisions, related to their work and 
home situation.  
 
Focus group interview 
To receive more in depth information on decision points 
and values involved in decision making, a focus group 
interview was organized. All focus group participants 
confirmed ‘starting with a treatment’, ‘dosing schedule’ 
and ‘method of administration’, and ‘transferring to 
another caregiver’ as important medical decision points 
(Figure 2). In addition, they mentioned ‘undergoing 
diagnostic procedures and check-ups for monitoring’ as a 
decision point. Values and preferences that are important 
for decision making were related to work, social 
participation, role in the family, quality of life, hobbies, 
leisure, social and psychological support. Patients also state 
Figure 1. PICO strategy 
 
PICO Definition 
 Population  Patients with metastatic or advanced breast cancer, male and female, and of all ages 
 Intervention  Decision aids or decision supportive tools or decision support or shared decision 
making 
 Comparison  Usual care 
 Outcome  All reported outcome measures for shared decision making 
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that they need to consider their own role in the decision 
making process. Patients stated they would like to receive 
support from healthcare professionals in getting insight 
into their own values and preferences. 
 
Interviews with healthcare professionals 
Both oncologists had experience with shared decision 
making with patients. Oncologists confirmed the following 
general decision points: ‘initiating treatment’, ‘stopping 
treatment’ or ‘proceeding with treatment’. Furthermore, 
they mentioned ‘starting with palliative chemotherapy’, 
‘proceeding to second or third line chemotherapy’, 
‘stopping with third line chemotherapy’, ‘choosing 
between different types of chemotherapy’ and ‘dosing 
schedule’ (Figure 2). Both oncologists experienced 
difficulties in the shared decision making process, since the 
number of administrations for each chemotherapy is 
limited to a maximum according to treatment protocols 
and guidelines, which narrows down the treatment 
options. According to the oncologists, most patients’ 
values or preferences within the deliberation process are 
related to aspects of quality of life and the home and work 
situation. Side-effects of a treatment, especially hair loss, 
age and expectations of others are important arguments 
for patients to reject a treatment. 
 
2. Which decision support tools are available 
for patients with metastatic breast cancer 
and what is their quality? 
 
To identify decision support tools for patients with 
metastatic breast cancer, we performed a systematic 
literature and internet search. 
 
Systematic literature and internet search  
The systematic literature search in Embase and Pubmed 
resulted in 133 articles. Only papers that concerned 
metastatic or advanced breast cancer, decision support 
tools, information on the development, evaluation or use 
of the decision aid were included. After applying the 
selection criteria, three articles remained. Two of these 
referred to the same decision aid. The internet search 
resulted in two additional decision aids (Figure 3). 
Consulting the international network of experts on shared 
decision making and experts of advanced breast cancer 
provided no additional relevant decision aids. 
 
Assessment of quality of available decision aids on 
metastatic breast cancer 
The quality of the four decision aids was assessed with the 
IPDAS criteria (Figure 2) by two independent researchers. 
Decision aid number 1 (Facing a treatment decision: 
Decision aid for patients with metastatic breast cancer 
considering chemotherapy) scored 60.4% on 53 criteria. 
The decision aid compares chemotherapy in addition to 
supportive care versus supportive care alone. The quality 
of the content and the effectiveness scored good (16 out 
of 23 resp. 6 out of 7 criteria). However, the decision aid 
does not provide any information or references regarding 
the development process and therefore scores low on the 
section ‘development process’ (10 out of 23 criteria). It 
contains a worksheet for patients to gain insight into their 
personal values and preferences. However, the decision aid 
contains a lot of text and the overall readability, scored 
with the SMOG criteria, is low.  
 
The second decision aid (Living with metastatic breast 
cancer: making the journey your own) scored 56.6% on 53 
criteria. It gives a general description of all treatment 
 
Figure 2. Overview of important decision points for patients with metastatic breast cancer 
 
Decision points Online 
questionnaire 
Patients 
Focus-
group 
Patients 
Interviews 
Caregivers 
 Should I participate in a scientific trial? x   
 Should I change the dosing schedule of the medication? x x x 
 Should I change the method of administration of the medication? x x  
 Should I start a treatment? x x x 
 Should I stop a treatment? x  x 
 Should I proceed with the treatment? x  x 
 Should I transfer to another treatment, caregiver or hospital? x x  
 Non-medical decisions, related to their work and home situation x   
 Should I undergo diagnostic procedures and check-ups for monitoring?  x   
 Should I start with palliative chemotherapy?   x 
 Should I proceed to second- or third line chemotherapy?   x 
 Should I stop with third line chemotherapy?   x 
 Which type of chemotherapy do I prefer?   x 
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options. This tool rates high on the criteria of the 
development process (18 out of 23 criteria). The decision 
aid does not provide data regarding survival, side-effects 
and associated risks specific for those treatment options, 
or more preferably, their subtypes. This decision aid 
scored sufficiently on readability, but due to the large 
amount of text, overall readability might be low. This tool 
provides examples of patients’ experiences with treatments 
to give more insight into which personal values and 
considerations are associated with the decision. However, 
the decision aid does not stimulate the patient to reflect on 
the meaning of this information for personal consideration 
(value clarification).  
 
The third decision aid, called palliative chemotherapy for 
mamma carcinoma, scored 42.0% on 50 criteria. The 
decision aid compares chemotherapy with the option of 
watchful waiting and provides information on survival, 
benefits and risks. However, the decision aid does not help 
the patient to gain insight into their own preferences 
regarding treatment options and outcomes. In addition, 
the decision aid scored low on development process (9 out 
of 20 criteria) and readability.  
 
The fourth decision aid, a video of the Mayo Clinic 
Interactive Breast Cancer Decision Tool, scored 16.0% on 
50 criteria. The video gives a general overview of breast 
cancer; such as anatomy, stage of disease and treatment 
options. This information, however, is too general in order 
to support patients and healthcare professionals in a 
shared decision making process. No information on 
benefits and risks of treatment options and no checklist to 
elicit values and preferences is presented.  
 
3. Which decision aid(s) should be developed? 
 
Important decision points that could be addressed in a 
decision aid according to patients and oncologist are:  
1. participating in a scientific trial 
2. dosing schedule and method of administering 
medication 
3. starting a treatment, stopping or proceeding treatment 
4. transferring to another treatment, caregiver or hospital 
5. non-medical decisions, related to work- and home 
situation 
6. undergoing diagnostic procedures and check-ups for 
monitoring, for example CT-scans 
7. starting with palliative chemotherapy 
8. changing type of, stopping or proceeding second or 
third line chemotherapy (i.e. a new variant of 
chemotherapy when the previous type causes for 
example too may side-effects, or the disease 
progresses) (Figure 2).  
 
The existing decision aids address medical decisions; two 
describe the choice between chemotherapy in addition to 
supportive care versus supportive care alone, one decision 
aid gives a description of all general treatment options and 
the option of ‘watchful waiting’ for patients with 
metastatic breast cancer and one gives a general overview 
 
Figure 3. Decision aids for patients with metastatic breast cancer and the scoring on the IPDAS criteria 
 
Decision aid Decision points IPDAS criteria 
  Content Development 
process† 
Effectiveness Total 
score 
(%) 
Facing a treatment decision: 
Decision aid for patients with 
metastatic breast cancer 
considering chemotherapy 
(English) Chiew et al.20 
Chemotherapy (yes or 
no) for patients who are 
resistant for hormone 
therapy 
16/23 10/23 6/7 60.4 
Living with metastatic breast 
cancer: Making the journey your 
own (English) – Dartmouth-
Hitchcock Medical Center21,22 
All treatment options 8/23 18/23 4/7 56.6 
Decision aid palliative 
chemotherapy for mamma 
carcinoma (Dutch) – 
RadboudUMC 23 
Chemotherapy (yes or 
no) 
10/23 9/20 2/7 42.0 
Mayoclinic: Interactive Breast 
Cancer Decision Tool (English) 
(http://www.mayoclinic.com) [not 
available anymore] 
General overview of 
breast cancer regarding 
for example anatomy, 
stage, type and 
treatment options 
4/23 3/20 1/7 16.0 
† Depending on the format and content of the decision aid, additional criteria were applied, causing the total number of 
criteria to vary between different decision aids. 
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of breast cancer, regarding for example disease stage, 
anatomy and general treatment options for all stages. 
Therefore, only a fraction of the mentioned decision 
points is covered in these decision support tools.  Finally, 
after discussing all results, the project team and experts 
advise to develop a decision aid for patients with 
metastatic breast cancer that addresses all mentioned 
decision points.  
 
Discussion 
 
From our study, we conclude that patients with metastatic 
breast cancer and their healthcare professionals face eight 
major preference-sensitive decision points during the care 
process. Furthermore, since available decision aids do not 
cover all these decision points, there is a need for a 
decision aid that addresses all identified decision points. 
 
Guidelines on breast cancer contain no explicit 
information on the advantages and disadvantages of the 
various treatment and care options for patients with 
metastatic breast cancer and their healthcare professionals. 
However, our study shows that patients with metastatic 
breast cancer and their healthcare professionals face eight 
major preference-sensitive decision points during the care 
process. For some of the mentioned decision points, 
decision support tools are available. However, none of the 
identified decision support tools covers all eight major 
decision points, due to the limited focus or the moderate 
quality of the decision aids. Therefore, the project team 
and experts decided to start the development of a decision 
aid that addresses the eight decision points and provides a 
personal value worksheet to help patients and healthcare 
professionals to explore the patient’s personal preferences 
and values. This decision aid will employ the relevant parts 
of the identified decision aids and correspond with the 
content of the Dutch guideline on breast cancer, in line 
with the advice of experts.12, 24, 25 
 
In 1995, a study by McQuellon26 emphasized that patients 
have clear preferences for specific treatments for 
metastatic disease. However, their preferred role in the 
decision making process varies among patients. In 
addition, individual patients' preferences often change in 
the course of the disease. In particular, in the last phase of 
life, patients often put more emphasis on weighing length 
of life against quality of life. For instance, in the decision 
whether or not to start treatment aimed at life 
prolongation, the possibility of side effects play an 
important role. Evidence suggests that informed patients 
elect for more conservative treatment options associated 
with more quality of life.27 Therefore, communication 
about patients' expectations, wishes and preferences for 
participation in treatment decisions is of great 
importance.28  In our study, both patients and healthcare 
professionals indicated the importance of communication 
on options and values for eight major decision points.  
In our study only two oncologists were interviewed and 
only one focus group with patients was held. This resulted 
in valuable qualitative data for considering the focus of the 
decision aid to be developed and the information needs of 
patients and their healthcare professionals. Preferably, 
more interviews and multiple focus groups should be 
conducted until no new answers were given (saturation). 
Although both oncologists and patients mentioned 
predominantly similar decision points, it might be possible 
that other patients, nurses, radiologists, surgeons and 
general practitioners express other decision points as well. 
Another limitation is the recruitment of patients; the 
patients interviewed, were contacted through the website 
of the Dutch Breast Cancer Association. Patients that 
responded to the questionnaire are active members within 
the metastatic breast cancer community and might have a 
different opinion about the major decision points than 
other patients. Third, all participants of the focus group 
were diagnosed with earlier stage breast cancer several 
years before receiving the diagnosis of metastatic breast 
cancer. There were no patients who did not have any 
history with early stage breast cancer in the focus group. 
Results of the focus group therefore might not completely 
reflect all decisions patients within the whole community 
of metastatic breast cancer face after diagnosis. Despite 
these limitations, this is the first study to give insight into 
the major decision points patients with metastatic breast 
cancer and healthcare professionals are facing during the 
care process. It is also one of the fewer studies that 
comprehensively describes the process of starting the 
development of a decision aid.  
 
This explorative study provides useful results which can be 
used in further research or the development of a decision 
aid for patients with metastatic breast cancer. Both 
patients and healthcare professionals were interviewed to 
obtain more in-depth knowledge about the decision points 
that patients with metastatic breast cancer encounter. 
Their responses and the analysis of available decision aids 
showed that there is a strong need for the development of 
a decision tool to support the decision making process 
relating to eight different decision points, in which the 
patient’s values and preferences are taking into account as 
well.  
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